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Summary
Objective: The purpose of this study was to determine whether osteogenic protein 1 (OP-1) would protect articular cartilage from degeneration
during the development of osteoarthritis (OA) in the rabbit anterior cruciate ligament transection (ACLT) model. Previous studies have shown
that OP-1 is vital to cartilage matrix integrity and repair, stimulates synthesis of cartilage matrix components, proteoglycans, and collagen, and
has a protective effect against catabolic mediators like matrix metalloproteinases and interleukin-1.
Methods: The rabbit ACLT model was used in which the anterior cruciate ligament was transected leading to OA. OP-1 was delivered to the
joint surgically for approximately 6 weeks by implantation of an Alzet osmotic pump into the medial thigh with a catheter threaded from the
pump into the knee joint. Forty rabbits (20 control and 20 experimental) had the ACLT surgery and implantation of the pump performed simul-
taneously. They were sacriﬁced after 9 weeks for analysis. The OA was graded using the Outerbridge classiﬁcation with India Ink staining.
Histological staining and histomorphometry with Hematoxylin & Eosin and Safranin O were performed to analyze OA progression and
semi-quantitative polymerase chain reaction (PCR) was performed for anabolic and catabolic genes.
Results: The experimental group had an average Outerbridge score of 1.8 vs 2.5 for the controls (P< 0.05). Histomorphometry showed 10.9%
surface deterioration or an average depression of 0.05 mm vs 22.3% and 0.1 mm for the controls (P< 0.05). Semi-quantitative PCR showed
a signiﬁcantly greater expression of aggrecan and collagen type II in the OP-1 treated cartilage when compared to controls and less expres-
sion of aggrecanase, a catabolic mediator.
Conclusions: OP-1 may have a potential beneﬁt in protecting articular cartilage during the development of OA.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA), the most common type of joint disease,
is a degenerative disorder resulting from the breakdown of
articular cartilage in synovial joints. There are many current
treatments available for OA ranging from the most conser-
vative to more surgical extremes. Conservative measures
begin with lifestyle modiﬁcations such as weight loss and
decreasing activity. Physical therapy is an option. Pharma-
cologic treatment in the form of nonsteroidal anti-inﬂamma-
tory drugs (NSAIDs) can alleviate symptoms. Another
mainstay of treatment has been intra-articular steroid injec-
tions1. A relatively new treatment is the injection of hyalur-
onan which improves joint lubrication and can decrease
pain2. If these conservative measures are not sufﬁcient,
there are a variety of surgical options as well, ranging
from arthroscopic procedures to total joint arthroplasty.
Total joint arthroplasty can be an effective cure for many
patients but it is reserved for those who have failed
conservative measures and are willing to undergo surgery1.
The deﬁciency of all of these current treatments is that they1We would like to thank Stryker Biotech for funding this research.
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600mainly target the symptoms of OA but do not address the
fundamental mechanism behind OA which is the destruc-
tion of articular cartilage. Therefore, a treatment which
would protect or regenerate cartilage on a more cellular
level would be desirable.
With age, articular cartilage degenerates on a cellular
level. There is a decrease in the number of chondrocytes
and proteoglycans leading to an overall loss of cartilage
height. The matrix loses water3e5. There are some current
treatment modalities that attempt to repair cartilage by re-
storing its structural integrity and function. These include
microfracture and autograft and allograft transplants into os-
teochondral defects. Although these methods repair articu-
lar cartilage, they do require a surgical procedure1. An
alternative biological therapy which prevents the natural
degradation of articular cartilage, and possibly even pro-
motes regeneration of cartilage, would be a desirable alter-
native. In this study, osteogenic protein 1 (OP-1) or bone
morphogenic protein 7 (BMP-7) was chosen as a novel tis-
sue engineering solution to protect articular cartilage from
degeneration during the development of arthritis.
OP-1 is a member of the transforming growth factor-beta
(TGF-beta) superfamily. The majority of its use thus far has
been for its osteogenic properties. Many studies have
shown that OP-1 induces bone formation and enhances
bone healing6. OP-1 is known to recruit stem cells from
the surrounding tissue and initiates the bone formation cas-
cade starting with osteoblast activity. OP-1 is already Food
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ternative to the patients’ own bone (autograft) in recalcitrant
long bone nonunions where autograft is unfeasible and al-
ternative treatments have failed.
Studies have also shown that OP-1 has many signiﬁcant
beneﬁts on cartilage tissue. Little has been done to measure
the effects of OP-1 on cartilage in vivo but there is a good
amount of in vitro research that shows a promising potential.
OP-1 is expressed naturally by human chondrocytes. It is
present in both normal and OA cartilages but mature OP-1
is downregulated in OA and degenerated cartilages7. There
can be up to a nine-fold decrease8. OP-1 is important for car-
tilagematrix integrity and repair. Anti-sense inhibition ofOP-1
resulted in a decrease in proteoglycan synthesis of 48 23%
and dramatic decrease in Safranin O and anti-aggrecan
staining9. OP-1 has a strong anabolic effect on cartilage by
stimulating synthesis of cartilage matrix components and in-
creasing proteoglycan and collagen synthesis10,11. It also
caused an upregulation of anabolic genes in OA chondro-
cytes compared to normal chondrocytes12. OP-1 also pro-
motes matrix assembly. It increased the synthesis of
hyaluronan and CD44 which are necessary for retention of
aggrecan and assembly of matrix13. Additional work has
been done with intervertebral disc cells that have shown
that OP-1 treatment increases total DNA, proteoglycan and
collagen levels in rabbit nucleus pulposus and annulus ﬁbro-
sis cells cultured in vitro14. These results support the choice
of OP-1 as a possible biological treatment for OA.
OP-1 has also been shown to antagonize catabolic medi-
ators of cartilage leading to a possible protective effect. It in-
hibited the hyaluronan hexasaccharide induced cartilage
matrix depletion in one study15. In another study, treatment
of human articular chondrocytes with OP-1 blocked the
downregualtion of proteoglycan synthesis caused by inter-
leukin-1 (IL-1)16. OP-1 also blocked the cartilage damage
caused by ﬁbronectin by preventing proteoglycan degrada-
tion17 and reduced matrix metalloproteinase-13 (MMP-13)
expression in chondrocytes which normally plays a patho-
logical role in the cartilage destruction of arthritis18. Interver-
tebral disc cells exposed to IL-1 also did not lose their
normal potential to upregulate proteoglycan synthesis
when stimulated with OP-119. All of these results further
support that OP-1 may have the capability to protect articu-
lar cartilage from degeneration, but they are only in vitro
studies. The goal of this study is to determine the effect of
OP-1 on articular cartilage in vivo using an animal model
for OA.Materials and methodsANTERIOR CRUCIATE LIGAMENT TRANSECTION (ACLT)
SURGERY AND IMPLANTATION OF ALZET OSMOTIC PUMPThe model used to study the development of OA in this study was the rab-
bit ACLT model. Previous studies have shown that this method produces
a reliable and reproducible degradation of articular cartilage after 9
weeks20,21.
After approval from the Institutional Animal Care and Use Committee
(IACUC) and University of California San Diego Animal Subjects Committee,
40 New Zealand white rabbits, each approximately 1 year old, were used for
this experiment. They were divided into two equal groups of 20, one control
and the other experimental. Each rabbit was initially sedated with xylocaine
and sodium pentobarbital (Abbott labs, North Chicago, IL) and then anesthe-
tized with isoﬂuorane gas (VEDCO Inc, St. Joseph, MO). Their right legs
were shaved, prepped and draped in the usual sterile fashion using beta-
dyne. An approximately 3 cm midline incision was made over the knee. After
dissection through subcutaneous tissues, the capsule was incised with a me-
dian parapatellar incision. The patella was dislocated laterally, exposing the
ACL which was then transected completely. An intraoperative Lachman test
was performed to verify that instability had been created.After performing the ACL transection, each animal underwent implanta-
tion of a sterile Alzet osmotic pump (Model 2004) with an attached intra-
articular catheter to deliver OP-1 to the joint. The pumps were buried under
the muscle of the medial thigh with the catheter from the pump passing into
the joint through a 2 mm drill hole in the metaphyseal bone of the medial con-
dyle and eventually entering the joint in the intra-articular notch. The catheter
was secured in place proximally and distally by polyethylene stents. The cap-
sule was then closed by a running 2-0 vicryl layer and the skin was closed
with an additional running 4-0 vicryl layer.
The experimental group of 20 rabbits received a continuous infusion of
OP-1 in 5% lactose buffer solution at a volume of 0.25 mL/h. Our lab has pre-
viously shown that the average volume of synovial ﬂuid in the rabbit knee is
equal to 0.35 mL based on joint space measurements22. The concentration
of OP-1 in the buffered solution was 70 mg/mL resulting in a constant syno-
vial ﬂuid concentration of approximately 50 ng/mL. This number was targeted
because a similar study performed by Jelic et al. in a sheep osteochondral
defect model had good results with this concentration23. The total amount
of OP-1 in the pump was about 250 mL and at the above ﬂow rate, the
pump was empty after approximately 6 weeks. The pump remained in place
until the animal was sacriﬁced, 9 weeks after the initial surgery, so as not to
expose the animals to another surgery. The control group of 20 rabbits re-
ceived the same pumps and delivery rate, however, the pumps were loaded
with only 5% lactose buffer solution with no OP-1. These pumps also deliv-
ered the buffer solution for approximately 6 weeks and remained in the ani-
mal until sacriﬁce.
Before beginning the study, the effectiveness of the Alzet osmotic pump
was ﬁrst tested in vivo by implanting it into a rabbit thigh with an intra-articular
catheter as described above. This test pump was ﬁlled with India Ink and the
animal was sacriﬁced 2 weeks after implantation, and grossly extravasation
of ink into the knee joint was observed. The above ﬂow rate and actual sy-
novial concentration were also tested by weekly synovial ﬂuid aspirations
on two additional rabbits who received the same ACLT surgery and implan-
tation of OP-1 pumps. OP-1 content and percent of oxidized species in OP-1
samples were determined by reduced reverse phase high pressure liquid
chromatography (rpHPLC) using a Waters Alliance 2695 Separations mod-
ule with a Waters 2487 Dual l Absorbance detector. Dried samples were sol-
ubilized in 8 M urea, 100 mM NaCl, 50 mM Tris, pH 8.0 buffer and were
reduced with b-mercaptoethanol. Separation was achieved on an ACE C4
(4.6 50 mm) column (MAC-MOD Analytical, Chadds Ford, PA) under a gra-
dient of 0.1% triﬂuoroacetic acid in water and 0.075% TFA in acetonitrile
(70e45% of 0.1% TFA and water over 11 min). Detection was at 215 nm.
The OP-1 content of each sample was determined by comparison of the
main peak area to a standard curve generated with OP-1 reference standard.
The relative percent of oxidized species was also determined from the peak
areas of species present. The procedure AM005-M03 ‘‘Reduced rpHPLC
with C4 column’’ was used as guidance. Data were processed using Em-
power 2 software. These synovial ﬂuid collections showed a concentration
of OP-1 from about 10 ng/mL to 100 ng/mL through 5 weeks, conﬁrming
that OP-1 was indeed being pumped into the joint at a synovial ﬂuid concen-
tration near the target of 50 ng/mL.
After surgery, rabbits were given appropriate postoperative care and
analgesia. All animals were allowed normal cage activity and sacriﬁced
9 weeks after surgery.ASSESSMENT: GROSS MORPHOLOGICALThe rabbit knees were harvested and initially put in a phosphate buffered
solution with protease inhibitors: 2 mM disodium-ethylenediaminetetraacetic
acid (Na2-EDTA), 1 mM phenylmethanesulphonylﬂuoride (PMSF), 5 mM ben-
zamidine hydrochloride (Benz-HCl), and 10 mM N-ethylmaleimide (NEM) for
1 h. The femoral condyleswere then stainedwith India Ink (HigginsWaterproof
Drawing Ink, Sanford Co of Bellwood, IL). The ink was applied to the surface of
the condyle with a small paintbrush and then excess was washed off with
a quick rinse of sterile water. The condyles were then photographed with a
Nikon Dx 5 mega-pixel digital camera (Nikon, Japan) for analysis.
Each condyle was assessed by three separate individuals who were
blinded to which group the condyle was in. They graded the condyles using
the Outerbridge classiﬁcation which is a well-known method of grading
cartilage after India Ink staining20,24e26. The criteria are as follows: Grade 1
(intact surface) e surface appears normal and does not retain any ink; Grade
2 (minimal ﬁbrillation) e site appears normal before staining but retains ink as
elongated specks or light gray patches; Grade 3 (overt ﬁbrillation) e the
cartilage is velvety in appearance and retains ink as intense black patches;
Grade 4 (erosion) e loss of cartilage exposing the underlying bone. Using
these grades, an average score for each condyle and for each entire group
was calculated.ASSESSMENT: HISTOLOGICALThe condyles were placed in 10% buffered neutral formalin with 1% cetyl-
pyridinium chloride at the time of harvest. The medial femoral condyle of
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Fig. 1. The ﬁgure illustrates the calculation of percent deterioration and average defect size. (A) An actual histologic section of cartilage. (B) A
projection of that section for calculations. In ﬁgure B, the red line represents the ideal cartilage surface, the blue line represents the ideal sub-
chondral plate and the black line represents the actual cartilage surface. The calculated area between the red and blue lines is the ideal car-
tilage area, while the calculated area between the black and blue lines is the actual cartilage area. One minus the ratio of actual area to ideal
area is the percent deterioration. The average defect is calculated as an average amount of depression from the red to black lines.
Table I
RT-PCR primers
GAPDH 293 base pairs (bp) (289e581), 55(C,
26 cycles (cy)
Sense 50-TCA CCA TCT TCC AGG AGC GA-30
Anti-sense 50-CAC AAT GCC GAA GTG GTC GT-30
Type II collagen 367 bp (1e367), 65(C, 28 cy
Sense 50-GCA CCC ATG GAC ATT GGA GGG-30
Anti-sense 50-GAC ACG GAG TAG CAC CAT CG-30
Aggrecan 206 bp (247e452), 58(C, 34 cy
Sense 5GAG GTC GTG GTG AAA GGT GT-30
Anti-sense 5-GTG TGG ATG GGG TAC CTG AC-30
MMP-3 363 bp (429e791), 65(C, 34 cy
602 N. Badlani et al.: The effect of OP-1 on osteoarthritiseach animal was used for histology. The specimens remained in the ﬁxative
for approximately 3 days. After the cartilage/bone core had been ﬁxed it was
decalciﬁed with 30% formic acid. The end point of decalciﬁcation was deter-
mined radiographically. After the cartilage/bone was completely decalciﬁed
the specimens were dehydrated with ascending alcohol grades: 70% (two
changes), 95% (two changes), and 100% (two changes) cleared with Histo
Clear and embedded in parafﬁn blocks. The blocks were sectioned on a ro-
tary microtome at 6 mm and placed on Superfrost Gold slides. The medial
femoral condyles were sectioned in the sagittal plane, perpendicular to the
bone. The slides were allowed to dry at room temperature overnight. The
slides/sections were heated in a slide drier at approximately 62C for
25 min, then allowed to return to room temperature before being stained
with Safranin O and Hematoxylin & Eosin (H&E).
H&E staining was done by ﬁrst placing the slides in Hematoxylin for 3 min,
followed by washes with ethanol and water and brieﬂy with lithium carbonate.
The slides were then placed in Eosin for 30 s followed by additional ethanol
and water washes.
Safranin-O staining was done by ﬁrst treating the samples with xylene fol-
lowed by ethanol and water washes and then treatment with the Fast Green
and Safranin-O stains with a wash of acetic acid between. Final washing was
then done with ethanol and xylene before mounting.
Histologic sections were then visualized with a Nikon Microphot micro-
scope and an attached Nikon E5700 5 mega-pixel digital camera, and
then scanned at high resolution (3600 dpi) for image analysis, using our pre-
viously described technique for histomorphometry27. Measurements were
made using ImageJ software (version 1.34s, National Institutes of Health,
Bethesda, MD). A proﬁle of the cartilage surface and subchondral plate
was generated and the xey coordinates copied into a Microsoft Excel
spreadsheet. The proﬁle data were used to deﬁne two idealized third order
polynomial curves which described the upper and lower limits of the cartilage
area. The ratio of the area of the zone ﬁlled with cartilage and the area of the
idealized zone was presented as the percentage repair (%rep). The percent-
age of deterioration was calculated as 1%rep. Cartilage depression in abso-
lute terms was determined as the average distance from the idealized
cartilage surface curve to the actual condylar surface27. Figure 1 illustrates
this technique.Sense 50-GCC AAG AGA TGC TGT TGA TG-30
Anti-sense 50-AGG TCT GTG AAG GCG TTG TA-30ASSESSMENT: BIOCHEMISTRYMMP-13 300 bp (742e1241), 55(C, 30 cy
Sense 50-AAC GAG GAT GAT GAT TTG GTC CG-30
Anti-sense 50-TTG GCC AGG AGG AAA AGC GTG AG-30
Aggrecanase 308 bp (50e357), 56(C, 34 cy
Sense 50-CTG TGC CGT GAT TGA AGA TG-30
Anti-sense 50-GCT GAG TGG CAT CGT AGG TTT-3
IL-1 354 bp (255e582), 58(C, 34 cy
Sense 50-TAC AAC AAG AGC TTC CGG CA-30
Anti-sense 50-GGC CAC AGG TAT CTT GTC GT-30
Each gene used is listed followed by the number of base pairs,
temperature of reaction, number of cycles, and the actual gene
sequences used.mRNA expression levels of anabolic and catabolic genes were deter-
mined by semi-quantitative real time polymerase chain reaction (RT-PCR)
as previously reported28,29. Articular cartilage was taken from the trochlea
of each femur and synovial tissue from the suprapatellar area. This cartilage
and synovial tissue were pulverized in liquid nitrogen, and total RNA was iso-
lated using the acid guanidinium thiocyanateephenol extraction procedure29.
Starting with 1 mg of total RNA, ﬁrst-strand cDNA was synthesized using
oligo (dT)15 primers.
Based on published sequences (BLAST) PCR primer sets speciﬁc to se-
lected coding regions of aggrecan, type II collagen, aggrecanase, matrix
metalloproteinase-3 (MMP-3), MMP-13, and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) were constructed (Table I). Cycle studies were un-
dertaken for all genes to determine the linear range of ampliﬁcation for each
gene. The appropriate cycle and temperature were then used for each
primer. National Institutes of Health (NIH) image analysis software (version1.61, National Institutes of Health, Bethesda, MD) was used to quantitatively
scan RT-PCR proﬁles following agarose gel electrophoresis and ethidium
bromide visualization. The NIH software measures relative mean density
over a ﬁxed gray scale range after correction for background. All values
were normalized to GAPDH. Data are expressed as mean mRNA expres-
sion standard deviation (SD) and evaluated using unpaired Student’s
t test. Statistical signiﬁcance was set at P< 0.05.ResultsGROSS MORPHOLOGICALAt the time of sacriﬁce, there was no appreciable evi-
dence of synovitis or bone formation. Therefore, these ﬁnd-
ings were not further analyzed microscopically but the
Control OP-1
Medial MedialLateral Lateral
Fig. 2. India Ink staining of control and OP-1 treated knees after sacriﬁce. The control group showed more areas of wear and greater depths of
ﬁbrillation.
603Osteoarthritis and Cartilage Vol. 16, No. 5synovium was used for PCR. No other side effects of treat-
ment were noted.
Each condyle was graded in a blinded fashion by three
separate observers. Figure 2 shows an example of a typical
control and OP-1 treated condyle stained with India Ink. The
mean score of each condyle and for each group was tabu-
lated. The mean Outerbridge score for the control group
was 2.5 with an SD of 0.78 while the OP-1 group had
a mean score of 1.8 with an SD of 0.77 [Fig. 3(A)], the lower
grade for the OP-1 group indicated less damage to the car-
tilage surface. This was a statistically signiﬁcant difference
(P¼ 0.017).
The average Outerbridge scores for each condyle were
also separated into groups from one to four to determine
a frequency of each score for each group. In the control
group, 46% of the condyles were graded 3 or 4, indicating
that they had a high degree of cartilage ﬁbrillation or loss.
In the OP-1 treated group, only 12% of the condyles were
graded either 3 or 4. Moreover, in the OP-1 treated group
28% of condyles showed Grade 1 or near normal cartilage
compared to just 7% in the control group. These data
shown in Fig. 3(B) conﬁrm a greater frequency of high grade
OA in the control group.HISTOMORPHOMETRYOn a microscopic level, the control group showed a signif-
icantly greater loss of cartilage than the OP-1 group.Mean Outerbridge Score
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Fig. 3. (A) Mean Outerbridge scores of the control group (n¼ 15) and
statistically different than the OP-1 group score of 1.8 (P¼ 0.017). (B) F
(n¼ 18) groFigure 4 shows a typical histological section from a control
group condyle and an OP-1 treated condyle. In percentage
terms, the average percent deterioration of the control
group was 22.3% of the ideal cartilage surface with an SD
of 12% vs a deterioration of only 10.9% for the OP-1 treated
group and an SD of 7.7% [Fig. 5(A)]. This was statistically
signiﬁcant (P¼ 0.004).
In absolute terms, the average depression of the cartilage
surface of the control group was 0.100 mm with an SD of
0.066 mm while the OP-1 treated group had an average de-
pression of exactly half of that at 0.051 mm and an SD of
0.042 mm [Fig. 5(B)]. This was statistically signiﬁcant
(P¼ 0.022). Additionally, no bony overgrowth was noted
microscopically.BIOCHEMISTRYBiochemically, the OP-1 treated cartilage showed some
increased expression of anabolic genes and decreased ex-
pression of catabolic genes when compared to the control
group. The anabolic genes, aggrecan and type II collagen,
had a higher expression in the OP-1 group when compared
to the control group at a P-value of less than 0.05. Three
catabolic genes were tested in the cartilage, MMP-3,
MMP-13, and aggrecanase. Aggrecanase showed a signiﬁ-
cantly lower expression in the OP-1 treated group when
compared to the control at a P-value of less than 0.05,
but there was no signiﬁcant difference in expression of28%
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Fig. 4. Sample histological sections of control group condyles and OP-1 treated condyles. The sections were taken perpendicular to the bone
in the sagittal plane from the medial femoral condyles. The control group sections showed a more irregular cartilage surface and less intact
cartilage.
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a semi-quantitative form of PCR. Although a signiﬁcant dif-
ference was shown for several of the genes tested, the
magnitude of that difference was not relatively large as
Fig. 6 shows.
Expression of the same three catabolic genes, MMP-3,
MMP-13, and aggrecanase, was tested in the synovial tis-
sue of the OP-1 treated group and the control group but
no signiﬁcant difference was found.Discussion
The aim of this study was to test the effect of OP-1 as
a novel therapeutic approach to reducing the progression
of OA in a rabbit ACLT model. This model has been used
successfully in the past in our laboratory. It is easily repro-
ducible and past studies have shown that it produces a con-
sistent degeneration of the articular cartilage in just 8
weeks20,21. One of the challenges then was to try and
decide the most effective way to deliver OP-1 to the joint
locally. The most obvious choice would be intra-articular% Cartilage Degeneration 
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Fig. 5. (A) Histomorphometry data showing the percent deterioration of ca
percent deterioration of the control group was 22.3% which was stati
(P¼ 0.004). (B) Histomorphometry data showing the average depressi
treated groups. The average depression of the control group was 0.100 m
of the OP-1 groupinjections. However, this method would pose many prob-
lems. First, it is challenging to inject a rabbit knee because
of its small volume, estimated to be just 0.35 mL22. Even if
the knee joints were successfully injected every time, the
small volume limits the amount that can be introduced
with each injection. Furthermore, each injection would re-
quire subjecting the animals to the risks of anesthesia. So
although multiple injections would have been more clinically
applicable, the decision was made to use a constant deliv-
ery device, the Alzet osmotic pump instead. The efﬁcacy of
the device was tested in vivo before beginning the study
with good results.
There have only been a few other in vivo studies which
have used OP-1 to treat cartilage lesions. The most similar
to this one was done by Jelic et al. in which an osteochon-
dral defect was made in sheep knees. These defects were
treated with a similar dose of OP-1 in an acetate solution by
means of the same osmotic pump for 2 weeks. The animals
were sacriﬁced at 3 months and 6 months, and the results
showed a consistent ﬁlling of the defect with new cartilage
while controls showed no evidence of new cartilage forma-
tion23. The study of Jelic et al. differs from this study in thatAverage Depression (mm)
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Fig. 6. RT-PCR data showing the expression of anabolic and catabolic genes in the cartilage tissue of the control (n¼ 12) and OP-1 (n¼ 12)
treated groups. The OP-1 treated cartilage showed a statistically signiﬁcant increase in type II cartilage and aggrecan expression and
decrease in aggrecanase expression when compared to the control group (P< 0.05).
605Osteoarthritis and Cartilage Vol. 16, No. 5the model employs an inciting trauma to the cartilage as op-
posed to a gradual breakdown caused by the ACLT. With
a traumatic model, there is a signiﬁcant initial inﬂammatory
response which could contribute to the regeneration of car-
tilage. Jelic et al. state that synovial mesenchymal cells are
triggered by the injury and are then driven to a cartilage lin-
eage by the presence of OP-1. In our study, there is no such
initial inﬂammatory cellular response, but instead a gradual
mechanical breakdown of the cartilage because of the knee
instability. This simulates OA and the results of the study
show that OP-1 does have a protective effect on the arti-
cular cartilage over time. The successful use of a similar
delivery system in both studies supports the fact that a con-
tinuous infusion of OP-1 at the dose used is an optimal way
to deliver the therapy.
Other in vivo studieswithOP-1havehadsimilar positive re-
sults but have used alternative delivery systems. Louwerse
et al. created subchondral defects in goat knees in their study.
They treated the defects with OP-1, but delivered OP-1 by
mixing it with autologous blood and autologous particles of
perichondrium and also covered the defect with a periosteal
ﬂap. They also found formation of new cartilage after 4
months30. The use of blood, perichondrium, and periosteum
though in addition to OP-1makes drawing conclusions about
the true effect of OP-1 itself somewhat complicated. Katic
et al. created a defect in thyroid cartilage of dogs. They
treated the defects with thyroid allografts which were soaked
withOP-1. The defectswere also coveredwith host perichon-
drium. They also found formation of new bone and cartilage
embedded into the defect at 4 months31. Conclusions about
their results, however, are also difﬁcult to make because of
the presence of allograft and perichondrium as part of the
treatment. Nevertheless, these results do support the ability
of OP-1 to regenerate articular cartilage, though they differ
from this current study because like the study of Jelic et al.,
their model is a single traumatic event rather than a gradual
process.
These studies raise the question of what is the most effec-
tive way to deliver OP-1. Clinically, injections would be the
most obvious choice. The only in vivo studies with OP-1
that have used injections as a delivery method have been
to treat intervertebral disc pathology. The injection of OP-1
into degenerated intervertebral discs resulted in an increase
in disk height and anassociated increase in collagen andpro-
teoglycan content in a rabbit model32,33. OP-1 injection alsoeffectively decreased the expression of key catabolic media-
tors like aggrecanase and MMP-13 in a rat model of interver-
tebral disc degeneration34. Although these results were not
from the treatment of articular cartilage, they do support the
possible delivery of OP-1 by injection.
The current study showed that a constant infusion of
OP-1 may be the most ideal form of delivery. On both mac-
roscopic and microscopic levels, the degradation of articular
cartilage was signiﬁcantly less when treated with OP-1.
There was also evidence of an increased expression of
key anabolic genes and decreased expression of an impor-
tant catabolic gene in the articular cartilage that had been
treated with OP-1. A limitation of this study was that the
magnitude of this difference was not relatively large.
Future studies will continue to study the effect of OP-1 on
the expression of important anabolic and catabolic media-
tors which may contribute to the mechanism by which
OP-1 exhibits a protective effect on articular cartilage, as
well as the optimal delivery systems and time course of
treatment for OP-1.Conclusions
OP-1 may have a potential beneﬁt in protecting articular
cartilage during the development of OA.Conﬂict of interest
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